877-277-7848

      RONKONKOMA, N.Y.–(BUSINESS WIRE)–ReCor
      Medical
      , an emerging medical device company, reported
      today six-month follow-up data on eight patients who have been treated
      via renal denervation for their resistant hypertension with the
      Company’s PARADISE® System—the only system for renal denervation that is
      based on ultrasound, not radiofrequency, energy.

      “These clinical results strongly suggest a significant competitive
      advantage for ReCor’s ultrasound-based PARADISE system
      compared to radiofrequency-based standard of care for
      treating resistant hypertension patients”

      At six months follow-up, the PARADISE data showed that
      office systolic blood pressure was reduced by an
      average of 33 mm Hg
      in 8 patients.
      Of note: there were also
      significant and sustained blood pressure reductions in home and
      ambulatory measurements at six months. The scientific literature
      demonstrates that only a 5 mm Hg reduction in BP results in a 14%
      decrease in stroke, a 9% decrease in heart disease, and a 7% decrease in
      mortality.

      “These clinical results strongly suggest a significant competitive
      advantage for ReCor’s ultrasound-based PARADISE system
      compared to radiofrequency-based standard of care for
      treating resistant hypertension patients,” said Mano Iyer, CEO,
      ReCor Medical.

      The PARADISE ultrasound catheter was designed with the aim to
      allow complete circumferential
      denervation more consistently and efficiently than the standard of care radiofrequency
      ablation catheter. The procedure with the PARADISE system only requires
      30 seconds of energy delivery per treatment location, thereby
      dramatically reducing the overall procedure time.

      ReCor also announced that it has published a collection of video
      interviews conducted during ‘EuroPCR 2012’ with key opinion
      leaders
      (KOLs) on the topic of RENAL DENERVATION to treat resistant
      hypertension
      . (Click link above to see these videos.)

      About ReCor Medical, Inc.

      Founded in 2009, ReCor is a private venture-backed, early-stage company
      developing novel therapeutic ultrasound catheter technology.
      ReCor is backed by European and U.S. investors including Sofinnova
      Partners, one of the largest life science investors in Europe. The
      Company’s PARADISE™ technology for renal denervation is CE-marked. For
      more information about ReCor Medical, please visit the Company’s website
      at www.recormedical.com.

      NOTE: PARADISE™ is approved for sale in Europe; it is not
      approved for sale or investigational use in the United States.